A- A A+

WHO legt Leitlinie zur somatischen Versorgung psychisch Kranker vor

Genf – Menschen mit schweren psychischen Störungen – mittelschwere bis schwere Depressionen, bipolare Störungen, Schizophrenie und andere psychotische Störungen – haben in der Regel eine Lebenserwartung, die zehn bis 20 Jahre kürzer ist als die der allgemeinen Bevölkerung. Darauf weist die Weltgesundheitsorganisation WHO hin. Die Mehrheit dieser vorzeitigen Todesfälle sei auf somatische Erkrankungen zurückzuführen. (aerzteblatt.de, 09.11.2018)

https://www.aerzteblatt.de/nachrichten/99031/WHO-legt-Leitlinie-zur-somatischen-Versorgung-psychisch-Kranker-vor

WHO Guidelines. Management of physical health conditions in adults with severe mental disorders

World Health Organization, Publication date: 2018, Languages: English, ISBN: 978-92-4-155038-3

http://www.who.int/mental_health/evidence/guidelines_physical_health_and_severe_mental_disorders/en/

Niederlande. Richtlijnen: Stoornissen in het gebruik van cannabis, cocaïne, amfetamine, ecstasy, GHB en benzodiazepines

(GGZ Standaarden - Dé online database met alle zorgstandaarden, richtlijnen en generieke modules,Niederlande, 26.02.2018)

https://www.ggzstandaarden.nl/richtlijnen/stoornissen-in-het-gebruik-van-cannabis-cocaine-amfetamine-ecstasy-ghb-en-benzodiazepines

EMCDDA. Best Practice Portal (Deutsch)

Das Best Practice Portal (Portal für vorbildliche Verfahren) soll Ihnen bei der Suche nach praktischen und verlässlichen Informationen über erfolgreiche (und wirkungslose) Maßnahmen in den Bereichen Prävention, Behandlung, Schadensminimierung und soziale Wiedereingliederung helfen. Hier können Sie schnell bewährte Interventionen ermitteln, Ihre Ressourcen effektiv planen und Ihre Maßnahmen durch die Anwendung von Tools, Standards und Leitlinien verbessern. (EMCDDA, Lissabon, Oktober 2018)

http://www.emcdda.europa.eu/best-practice_de

International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.

Crunelle CL, van den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, van de Glind G, Demetrovics Z, Coetzee C, Luderer M, Schellekens A; ICASA consensus group, Matthys F.

Eur Addict Res. 2018;24(1):43-51. doi: 10.1159/000487767.

https://www.karger.com/Article/FullText/487767

Opioid agonist treatment Guiding principles for legislation and regulations (Pompidou Group)

Expert group on the regulatory framework for the treatment of opioid dependence syndrome and the prescription of opioid agonist medicines. (Pompidou Group/Counsil of Europe, Co-operation Group to Combat Drug Abuse and Illicit Trafficking in Drugs, 2018, engl./frz.)

http://fileserver.idpc.net/library/2017_PPG_15_OAT_GuidingPrinciples_Final_ENG.pdf.pdf

Kanada. Management of opioid use disorders: a national clinical practice guideline

Julie Bruneau, Keith Ahamad, Marie-Ève Goyer, Ginette Poulin, Peter Selby, Benedikt Fischer, T. Cameron Wild and Evan Wood; on behalf of the CIHR Canadian Research Initiative in Substance Misuse

CMAJ March 05, 2018 190 (9) E247-E257; doi.org/10.1503/cmaj.170958

http://www.cmaj.ca/content/190/9/E247

Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion (Version 7 vom 29.11.2017)

Deutsche AIDS-Gesellschaft, Österreichische AIDS-Gesellschaft

https://daignet.de/site-content/hiv-therapie/leitlinien-1/Deutsch%20Osterreichische%20Leitlinien%20zur%20antiretroviralen%20Therapie%20der%20HIV%201%20Infektion.pdf

Kanada. Best Practice Guidelines: Implementing Supervised Injection Services

(Registered Nurses’ Association of Ontario, Februar 2018)

http://rnao.ca/sites/rnao-ca/files/bpg/Implementing_supervised_injection_services.pdf

As the NAS Crisis Worsens, a New Study Offers Treatment Guidelines

The incidence of neonatal abstinence syndrome (NAS) has been climbing steadily, according to a 2016 Morbidity and Mortality Weekly Report from the Centers for Disease Control and Prevention (CDC). The report, published August 12, indicated that the number of NAS cases rose from 1.5 per 1,000 hospital births in 1999 to 6 per 1,000 in 2013.

Yet guidelines for treating NAS have been lacking, according to a study in JAMA Pediatrics. The study, published online June 18, found that although several different approaches are being used, “no universal evidence-based pharmacological treatment strategy exists.” The article also noted that the FDA hasn’t approved any drug for treating infants who have NAS.

The authors of the JAMA Pediatrics study said that, without clear treatment guidelines, caregivers have typically chosen either methadone or morphine to treat their young NAS patients.

New Guidelines

Which medication—methadone or morphine—is better, and how to decide on an appropriate dose? Some studies have suggested basing the dose on the infant’s weight; others, on the severity of NAS, as assessed by the Finnegan Neonatal Abstinence Scoring System.

The JAMA Pediatrics team set out to answer the medication questions. They designed a treatment plan, then carried out what they believe is the first multisite, double-blind, randomized trial comparing the safety and efficacy of methadone and morphine in NAS. They published their results online June 18. (atforum.com, USA, 04.09.2018)

http://atforum.com/2018/09/nas-crisis-worsens-study-offers-treatment-guidelines/

Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline.

Lapoint J, Meyer S, Yu CK, Koenig KL, Lev R, Thihalolipavan S, Staats K, Kahn CA.

West J Emerg Med. 2018 Mar;19(2):380-386. doi: 10.5811/westjem.2017.11.36368.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851514/

USA. Johns Hopkins experts create opioid prescribing guidelines for 20 common surgical procedures

A Johns Hopkins expert panel of health care providers and patients have announced what is, to their knowledge, the nation's first set of operation-specific opioid prescribing guidelines. The guidelines are based on the premise that opioid prescribing limits should be based on the operation performed rather than a blanket approach. The ranges offered for each of 20 common operations generally call for reductions from the current rates of opioid prescription, and the researchers say that patients themselves favor using less of the drugs than physicians often prescribe. (Johns Hopkins University School of Medicine, USA, 14.08.2018)

https://medicalxpress.com/news/2018-08-johns-hopkins-experts-opioid-guidelines.html

USA. SAMHSA publishes guidance on clinical best practices using medication-assisted treatment to combat the opioid epidemic

The Substance Abuse and Mental Health Services Administration (SAMHSA) is publishing guidance today to help broaden healthcare professionals’ understanding of medications that can be used to treat Americans with opioid use disorder (OUD).

“We know that people can and do recover from opioid use disorders when they receive appropriate treatment, and medication-assisted treatment’s success in treating opioid use disorders is well documented,” said Dr. Elinore F. McCance-Katz, Assistant Secretary for Mental Health and Substance Use. “TIP 63 emphasizes that increasing access to medications to treat opioid use disorder will help more people recover, enabling them to improve their health, living full and productive lives.”

The Treatment Improvement Protocol (TIP) 63, “Medications for Opioid Use Disorder,” reviews the use of the three Food and Drug Administration-approved medications to treat opioid use disorders: methadone, naltrexone, and buprenorphine. Mandated by Section 303 of the Comprehensive Addiction and Recovery Act (P.L. 114-198), this TIP provides guidance for healthcare professionals and addiction treatment providers on appropriate prescribing practices for these medications and effective strategies for supporting the patients utilizing medication for the treatment of OUD. TIP 63 also educates patients, families, and the general public about how OUD medications work and the benefits they offer. The Substance Abuse and Mental Health Services Administration (SAMHSA), 15.02.2018)

https://www.samhsa.gov/newsroom/press-announcements/201802150200

WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection

WHO, Number of pages: 108; Publication date: July 2018; Languages: English; ISBN: 978-92-4-155034-5

These guidelines aim to provide evidence-based recommendations on the care and treatment of persons diagnosed with chronic HCV infection. They update the care and treatment section of the WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection issued in April 2016. The 2017 Guidelines on hepatitis B and C testing update the screening section.

http://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf

USA-SAMHSA. TIP 63: Medications for Opioid Use Disorders – Full Document (Including Executive Summary and Parts 1-5)

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat opioid use disorder (OUD)—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. (SAMHSA), 2/2018)

https://store.samhsa.gov/product/SMA18-5063FULLDOC

A survey of tobacco dependence treatment guidelines content in 61 countries

Kapka Nilan, Ann McNeill, Rachael L. Murray, Tricia M. McKeever and Martin Raw 

Addiction, Volume 113, Issue8, August 2018, Pages 1499-1506

First published: 28 February 2018, doi.org/10.1111/add.14204

https://onlinelibrary.wiley.com/doi/full/10.1111/add.14204

Simplified guideline for prescribing medical cannabinoids in primary care. 

Allan GM, Ramji J, Perry D, Ton J, Beahm NP, Crisp N, et al. 

Can Fam Physician. 2018;64:111–20. (Eng), e64–75 (Fr).

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964385/

APA: Pharmacological Treatment of Patients with Alcohol Use Disorder

The Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder was approved by the APA Assembly in May and by the APA Board of Trustees July 2017. (APA – American Psychiatric Association, Clinical Practice Guidelines, 05.02.2018)

https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines

Inpatient and Outpatient Treatment Programs for Substance Use Disorder: A Review of Clinical Effectiveness and Guidelines [Internet].

Ho C, Adcock L.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Nov 7.

https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0099460/

Handbuch Substitutionsbehandlung in Oberösterreich

Sachverständigenkommission zur regionalen Koordination der Substitutionsbehandlung

Linz, 2016

Version 2.0

https://www.land-oberoesterreich.gv.at/Mediendateien/Formulare/DokumenteAbt_San/Ges_Handbuch_Substitutionsbehandlung.pdf

Deutsch-Österreichische Leitlinien zur HIV-Präexpositionsprophylaxe

Klassifikation: S2k, AWMF-Register-Nr.: 055-008, Federführung: Deutsche AIDS-Gesellschaft (DAIG), 24.5.2018

https://daignet.de/site-content/hiv-therapie/leitlinien-1/Leitlinie%20PrEP%20055-008%20Version%201%20vom%2024-05-2018%20konsentiert%2022-06-2018.pdf

Guidelines on the management of co-occurring alcohol and other drug and mental health conditions in alcohol and other drug treatment settings

NHMRC Centre of Research Excellence in Mental Health and Substance Use, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia; 2016

https://comorbidity.edu.au/sites/default/files/National%20Comorbidity%20Guidelines%202nd%20edition.pdf

USA. Scientific guidelines for using cannabis to treat stress, anxiety and depression

PULLMAN, Wash.--In a first-of-a-kind study, Washington State University scientists examined how peoples' self-reported levels of stress, anxiety and depression were affected by smoking different strains and quantities of cannabis at home. (Washington State University, 19.04.2018)

https://www.eurekalert.org/pub_releases/2018-04/wsu-sgf041818.php

Deutsch-Österreichische Leitlinien zur Postexpositionellen Prophylaxe der HIV-Infektion

Federführung: Deutsche AIDS-Gesellschaft (DAIG)

unter Beteiligung der folgenden Fachgesellschaften:

•Österreichische AIDS-Gesellschaft (ÖAIG)

•Deutschen AIDS-Hilfe (DAH)

•Bundeszentrale für gesundheitliche Aufklärung (BZgA)

•Nationales Referenzzentrum für Retroviren, Universitätsklinikum Frankfurt

•Robert Koch-Institut (RKI)

•Kompetenznetz HIV/AIDS

Annahme der aktuellen Version durch Mitgliederbeschluss der Deutschen AIDS Gesellschaft (DAIG) am 13.06.2013

https://www.aidshilfe.de/sites/default/files/documents/Deutsch-Osterreichische%20Leitlinien%20zur%20Postexpositionellen%20Prophylaxe%20der%20HIV-Infektion.pdf

UK. Guidance: Drug misuse and dependence: UK guidelines on clinical management - How clinicians should treat people with drug misuse and drug dependence problems.

Published 14 July 2017, Last updated 15 December 2017

Government of UK, Department of Health

This 2017 version offers new guidelines on:

prison-based treatment

new psychoactive substances and club drugs

mental health co-morbidity

misuse of prescribed and over-the-counter medicines

stopping smoking

preventing drug-related deaths, including naloxone provision

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/668611/clinical_guidelines_2017.pdf

Open letter on the UNODC/WHO International Standards for the Treatment of Drug Use Disorders

We, the undersigned civil society organisations working at the national, regional and international level on issues related to drug use, drug treatment, harm reduction and drug policies, are writing to you today regarding the joint UNODC and WHO publication entitled International Standards for the Treatment of Drug Use Disorders.

The ‘Draft for Field Testing’ of this document (March 2017) raises serious concerns and contains significant omissions and misrepresentations. We request your urgent action to prevent these Standards being released in their current state. (Unterzeichnet von 188 Organisationen, 08.03.2018)

http://www.inpud.net/sites/default/files/2018-03%20CSO%20Letter%20on%20the%20International%20Standards%20FINAL.pdf